apo-methylphenidate
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2022 (NCT05414058)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05414058 | Phase 2 | Sep 9, 2022 | University of Ottawa |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Ottawa | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1